Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIMATINIB: Imatinib Dose Optimization in Newly Diagnosed CP-CML
NCT02896842Phase 2Completed
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Sep 2010
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imatinib in chronic myeloid leukemia (CML) (3 arms), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Major Molecular Response at 12 months. Started Sep 2010; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02896842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02896842.